BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
BioCryst Pharmaceuticals announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial…
Read More...
Read More...
